24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

• tafluprost (Drug), also known as Saflutan, Taflotan
• tafluprost and dorzolamide/timolol (Drug), also known as Saflutan, Taflotan, Cosopt PF

Primary outcomes

• Mean 24-hour efficacy (average intraocular pressure readings over 24 hours) [3 months]

Secondary outcomes

• Mean 24-hour peak intraocular pressure [3 months]
• Mean 24-hour fluctuation of intraocular pressure [3 months]
• Corneal staining [3 months]
• Break-up time of tear film [3 months]

Sex: All, ages: 21 Years to 85 Years

Inclusion criteria

* Open-angle glaucoma patients (primary open-angle glaucoma, exfoliative, or pigmentary glaucoma) insufficiently controlled on branded, or generic latanoprost monotherapy (IOP > 20 mm Hg as determined by 2 separate IOP measurements at 10:00 ± 1 hour)
* Patients with signs, or symptoms of ocular surface disease.
* Only those open-angle glaucoma subjects who, according to the opinion of the principal investigator, require further IOP reduction.
* Patients must have demonstrated at least 20% IOP reduction at 10:00 (± 1 hour) and who are treated with branded, or generic latanoprost monotherapy for at least 3 months.
* Only subjects with open-angle glaucoma that have exhibited (prior to latanoprost therapy) untreated, sitting IOP evaluated with Goldmann tonometry between 25-39 mm Hg at 10:00 (± 1 hour).
* Age between 21-85 years
* Mild to moderate glaucomatous disc damage and visual field loss (less than -12 dB mean deviation visual field loss attributed to glaucoma
* Those with 0.8 or better vertical cup-to-disc ratio and visual acuity greater than 0.1 in the study eye.
* Open anterior chamber angles.
* Those who have to demonstrate a reliable visual field (at least two visual fields with less than 20% fixation losses, false positives, or negatives)
* Patients who understand study instructions, are willing to attend all follow-up appointments and will comply with study medication usage.

Exclusion criteria

* Patients with a history of less than 10% IOP decrease on any IOP-lowering medication.
* Those with evidence of concurrent conjunctivitis, keratitis, or uveitis in either eye.
* Subjects with a history of inadequate adherence; intolerance, or contraindication to either prostaglandins, β-blockers, dorzolamide, or benzalconium chloride (BAK)
* Patients with severe ocular surface disease, previous intraocular conventional or laser surgery in the study eye (within 6 months prior to enrolment); previous history of ocular trauma; use of corticosteroids (within 3 months before the enrolment) and use of contact lenses.
* Those that on baseline examination show clinical evidence of inflammation, signs of ocular infection (except blepharitis), signs of any corneal abnormality that will affect subsequent IOP measurements
* Subjects that show unwillingness to participate in the trial.
* Females of childbearing potential or lactating mothers.

• Results publication: Konstas AG, Boboridis KG, Kapis P, Marinopoulos K, Voudouragkaki IC, Panayiotou D, Mikropoulos DG, Pagkalidou E, Haidich AB, Katsanos A, Quaranta L. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. Adv Ther. 2017 Jan;34(1):221-235. doi: 10.1007/s12325-016-0448-9. Epub 2016 Dec 2. PMID 27913991

• Anastasios G Konstas, MD, PhD, Principal investigator, Chair